Cancer surgery is a critical step in the treatment of many types of cancer. The goal in all cancer surgeries is to remove all of the cancerous tissue; however, surgeons do not have adequate tools to immediately detect cells left behind after initial resection. The only way to detect these cells today is to wait for the definitive pathology report to come back – days after the surgery is complete. In as many as 30% of cases, pathology finds that cancer was left behind, typically resulting in a second surgery and increased complication rates for these patients.
Lumicell aims to change this. The company’s lead product, the Lumicell System, is in late-stage development for breast cancer surgery. It features an investigational onco-fluorescent agent and a handheld imaging device that enable cancer surgeons to see and remove cancer cells in real-time during operations, with the goal of reducing or eliminating second surgeries.
Lumicell completed a Phase 1 safety study at Duke University Medical Center in the lead indications of breast cancer and sarcoma, and a Phase 2 feasibility study at Massachusetts General Hospital in breast cancer surgery. The company is starting its pivotal study in breast cancer, and is now being clinically evaluated in seven different cancer types, in 17 medical centers across the U.S. More information on Lumicell’s clinical trials can be found here.
CAUTION – New Drug and Investigational device. Limited by Federal (or United States) law to investigational use.